Advertisement

Size-Based Enrichment Technologies for CTC Detection and Characterization

  • Anthony Williams
  • Marija Balic
  • Ram Datar
  • Richard Cote
Chapter
Part of the Recent Results in Cancer Research book series (RECENTCANCER, volume 195)

Abstract

The degree of metastatic outspread in malignant disease is one of the leading factors in determining the appropriate course treatment. Circulating tumor cells (CTCs) represent the population of cells that have acquired the means to gain access to the circulatory system, and the cell population ultimately responsible for the development of metastases at distant sites in the body. While promising as a biomarker for metastatic disease, the widespread study of CTCs has been limited by their rarity, as CTCs are reported to occur as infrequently as 1/mL of whole blood. In this text, we will discuss current and emerging technologies for the size-based enrichment of CTCs from whole blood, and compare some of the advantages and disadvantages of using a size-based approach to CTC enrichment versus affinity-based CTC enrichment platforms.

Keywords

Circulate Tumor Cell Laser Capture Microdissection Castration Resistant Prostate Cancer Normal Healthy Donor Enrichment Technology 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Bidard FC, Vincent-Salomon A, Sigal-Zafrani B, Dieras V, Mathiot C, Mignot L, Thiery JP, Sastre-Garau X, Perga JY (2007) Prognosis of women with stage IV breast cancer depends on detection of CTC rather than disseminated tumor cells. Ann Oncol 19:496–500CrossRefGoogle Scholar
  2. 2.
    Cristofanilli M, Budd T, Ellis MJ, Stopeck A, Matera J, Miller C et al (2004) Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med 351:781–791PubMedCrossRefGoogle Scholar
  3. 3.
    Cristofanilli M, Hayes DF, Budd GT, Ellis MJ, Stopeck A, Reuben JM et al (2005) Circulating tumor cells: a novel prognostic factor for newly diagnosed metastatic breast cancer. J Clin Oncol 23:1420–1430PubMedCrossRefGoogle Scholar
  4. 4.
    Danila DC, Heller G, Gignac GA, Gonzalez-Espinoza R, Anand A, Tanaka E et al (2007) Circulating tumor cell number and prognosis in progressive castration-resistant prostate cancer. Clin Cancer Res 13:7053–7058PubMedCrossRefGoogle Scholar
  5. 5.
    Hayes DF, Cristofanilli M, Budd GT, Ellis MJ, Stopeck A, Miller MC et al (2006) Circulating tumor cells at each follow-up time point during therapy of metastatic breast cancer patients predict progression-free and overall survival. Clin Cancer Res 12:4218–4224PubMedCrossRefGoogle Scholar
  6. 6.
    Cohen SJ, Punt CJA, Iannotti N, Saidman BH, Sabbath KD, Gabrail NY, et al (2009) Prognostic significance of circulating tumor cells in patients with metastatic colorectal cancer. Ann Oncol l 20(7):1223–1229Google Scholar
  7. 7.
    Fleischer RL, Alter HW, Furman SC, Price SB, Walker RM (1972) Particle track etching. Science. 178:255–263PubMedCrossRefGoogle Scholar
  8. 8.
    Vona G, Sabile A, Malek L, Veronique S, Serge R, Schutze K et al (2000) Isolation by size of epithelial tumor cells: a new method for the immunomorphological and molecular characterization of circulating tumor cells. Am J Pathol 156:57–63PubMedCrossRefGoogle Scholar
  9. 9.
    Pinzani P, Salvadori B, Simi L, Bianchi S, Distante V, Cataliotti L et al (2006) Isolation by size of epithelial tumor cells in peripheral blood of patients with breast cancer: correlation with real-time reverse transcriptase-polymerase chain reaction results and feasibility of molecular analysis by laser microdissection. Hum Pathol 37(6):711–718PubMedCrossRefGoogle Scholar
  10. 10.
    Hou JM, Krebs M, Ward T, Sloane R, Priest L, Hughes A et al (2011) Circulating tumor cells as a window on metastasis biology in lung cancer. Am J Pathol 178(3):989–996PubMedCrossRefGoogle Scholar
  11. 11.
    De Giorgi V, Pinzani P, Salvianti F, Panelos J, Paglierani M, Janowska A et al (2010) Application of a filtration- and isolation-by-size technique for the detection of circulating tumor cells in cutaneous melanoma. J Invest Dermatol 130:2440–2447PubMedCrossRefGoogle Scholar
  12. 12.
    Gutschi T, Pachernegg O, Lackner K, Hutterer GC, Stauber R, Pummer R et al (2010) Detection of circulating tumor cells in patients with renal cell carcinoma compared with a control group. J Clin Oncol 28:15s (suppl; abstr 4618)Google Scholar
  13. 13.
    Zheng S, Lin H, Liu JQ, Balic M, Datar R, Cote RJ et al (2007) Membrane microfilter device for selective capture, electrolysis and genomic analysis of human circulating tumor cells. J Chroma A 1162:154–161CrossRefGoogle Scholar
  14. 14.
    Lin H, Zheng S, Williams A, Balic M, Groshen S, Scher HI et al (2010) Portable filter-based microdevice for detection and characterization of circulating tumor cells. Clin Cancer Res 16:5011–5018PubMedCrossRefGoogle Scholar
  15. 15.
    Zheng S, Lin HK, Lu B, Williams A, Datar R, Cote RJ et al (2011) 3D microfilter device for viable circulating tumor cell (CTC) enrichment from blood. Biomed Microdevices 13:203–213Google Scholar
  16. 16.
    Xu T, Lu B, Tai YC, Goldkorn A (2010) A cancer detection platform which measures telomerase activity from live circulating tumor cells captured on a microfilter. Cancer Res 70(16):6420–6426PubMedCrossRefGoogle Scholar
  17. 17.
    Bhagat AAS, Hou HW, Li LD, Lim CT, Han J (2011) Pinched flow coupled shear-modulated inertial microfluidics for high-throughput rare blood cell separation. Lab Chip 11:1870–1878Google Scholar
  18. 18.
    Maheswaran S, Sequist LV, Nagrath S, Ulkus L, Brannigan B, Collura CV et al (2008) Detection of mutations in EGFR in circulating lung cancer cells. N Engl J Med 359:366–377PubMedCrossRefGoogle Scholar
  19. 19.
    Gleghorn JP, Pratt ED, Denning D, Liu H, Bander N, Tagawa ST et al (2009) Capture of circulating tumor cells from whole blood of prostate cancer patients using geometrically enhanced differential immunocapture (GEDI) and a prostate-specific antibody. Lab Chip 10:27–29PubMedCrossRefGoogle Scholar
  20. 20.
    Williams A, Datar R, Cote R (2010) Technologies and methods used for the detection, enrichment and characterization of cancer stem cells. Natl Med J India 23(6):346–350PubMedGoogle Scholar
  21. 21.
    Stott SL, Hsu CH, Tsukrov DI, Yu M, Miyamoto DT, Waltman BA et al (2010) Isolation of circulating tumor cells using a microvortex-generating herringbone-chip. Proc Natl Acad Sci U S A 107(43):18392–18397PubMedCrossRefGoogle Scholar
  22. 22.
    FDA 510(k) #K050245 pre-market notification of intent to market device, March 15, 2005Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2012

Authors and Affiliations

  • Anthony Williams
    • 1
  • Marija Balic
    • 2
  • Ram Datar
    • 1
  • Richard Cote
    • 1
  1. 1.Department of PathologyUniversity of Miami-Miller School of MedicineMiamiUSA
  2. 2.Division of Oncology, Department of Internal MedicineMedical University of GrazGrazAustria

Personalised recommendations